Biblio

Found 53 results
Author Keyword Title Type [ Year(Asc)]
Filters: Author is Andreas du Bois  [Clear All Filters]
2014
F. Trillsch, Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., de Gregorio, N., Fotopoulou, C., Schmalfeldt, B., Burges, A., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Baumann, K. H., Keyver-Paik, M. D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schröder, W., Muenstedt, K., Richter, B., Kommoss, F., Hauptmann, S., and du Bois, A., Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study, Ann Oncol, vol. 25, pp. 1320-7, 2014.
P. Harter, Gershenson, D., Lhomme, C., Lecuru, F., Ledermann, J. A., Provencher, D. M., Mezzanzanica, D., Quinn, M., Maenpaa, J. U., Kim, J. - W., Mahner, S., Hilpert, F., Baumann, K. H., Pfisterer, J., and du Bois, A., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S5-8, 2014.
N. Simon Reed, Pautier, P., Åvall-Lundqvist, E., Choi, C. - H., du Bois, A., Friedlander, M. Leonard, Fyles, A., Kichenadasse, G., Provencher, D. M., and Ray-Coquard, I., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S30-4, 2014.
A. du Bois, Floquet, A., Kim, J. - W., Rau, J., Del Campo, J. M., Friedlander, M. Leonard, Pignata, S., Fujiwara, K., Vergote, I. B., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M. - A., Kim, J. - H., Kurzeder, C., Lesoin, A., Vasey, P. A., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B. - G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R. J., and Harter, P., Incorporation of pazopanib in maintenance therapy of ovarian cancer., J Clin Oncol, vol. 32, no. 30, p. 3382, 2014.
2011
G. C. E. Stuart, Kitchener, H. C., Bacon, M., du Bois, A., Friedlander, M. Leonard, Ledermann, J. A., Marth, C., Thigpen, T., and Trimble, E. L., 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference., Int J Gynecol Cancer, vol. 21, no. 4, pp. 750-5, 2011.
G. J. S. Rustin, Vergote, I. B., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G. B., Jakobsen, A., Sagae, S., Greven, K., Parmar, M. K. B., Friedlander, M. Leonard, Cervantes, A., Vermorken, J. B., and Intergroup, G. Cancer, Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), Int J Gynecol Cancer, vol. 21, pp. 419-23, 2011.
T. Thigpen, du Bois, A., McAlpine, J., DiSaia, P., Fujiwara, K., Hoskins, W. J., Kristensen, G. B., Mannel, R., Markman, M., Pfisterer, J., Quinn, M., Reed, N. Simon, Swart, A. Marie, Berek, J. S., Colombo, N., Freyer, G., Gallardo, D., Plante, M., Poveda, A. M., Rubinstein, L., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., First-line therapy in ovarian cancer trials., Int J Gynecol Cancer, vol. 21, no. 4, pp. 756-62, 2011.
C. Kurzeder, L, Z., Eisenhauer, E., Vergote, I. B., du Bois, A., D, T., Y, W., JF, G., HW, H., B, R., LC, H., Bentley, J., Wagner, U., Plante, M., Kimmig, R., and Pfisterer, J., The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. , J Clin Oncol , vol. 29, no. suppl; abstr 5088, 2011.
T. J. Perren, Swart, A. Marie, Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K. B., and Oza, A. M., A phase 3 trial of bevacizumab in ovarian cancer., N Engl J Med, vol. 365, no. 26, p. 2496, 2011.
P. Harter, Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., Hanker, L., Pölcher, M., Kurzeder, C., Canzler, U., Petry, K. Ulrich, Obermair, A., Petru, E., Schmalfeldt, B., Lorusso, D., and du Bois, A., Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO., Int J Gynecol Cancer, vol. 21, no. 2, p. 295, 2011.
E. Greimel, Bjelic-Radisic, V., Pfisterer, J., Hilpert, F., Daghofer, F., Pujade-Lauraine, E., du Bois, A., Group, A. Gynaekolog, and de l'Ovaire, Gd'Investig, Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials, Support Care Cancer, vol. 19, pp. 1421-7, 2011.

Pages